Showing results (351-360 of 757) with videos related to
Sort By:
Pageof 76
Clinical Therapeutics|October 4, 2016
Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 DiabetesTim Heise, Jens Jordan, Christoph Wanner, et al.Cardiovascular Diabetology|July 11, 2024
Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trialDavid Fitchett, Bernard Zinman, Silvio E Inzucchi, et al.Journal of Diabetes and Its Complications|September 18, 2022
Chronic kidney disease and cognitive decline in patients with type 2 diabetes at elevated cardiovascular riskChloë Verhagen, Jolien Janssen, Crista A Minderhoud, et al.Clinical Kidney Journal|August 14, 2024
Reduction in kidney function decline and risk of severe clinical events in agalsidase beta-treated Fabry disease patients: a matched analysis from the Fabry RegistryJulie L Batista, Ali Hariri, Manish Maski, et al.Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|June 7, 2021
Cardiac biomarkers in chronic kidney disease are independently associated with myocardial edema and diffuse fibrosis by cardiovascular magnetic resonanceLuca Arcari, Juergen Engel, Tilo Freiwald, et al.JACC. Cardiovascular Imaging|June 18, 2011
Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessmentMarkus Niemann, Sebastian Herrmann, Kai Hu, et al.Atherosclerosis|August 3, 2007
Native C-reactive protein induces endothelial dysfunction in ApoE-/- mice: implications for iNOS and reactive oxygen speciesSusanne B Schwedler, Peter J Kuhlencordt, P Padmapriya Ponnuswamy, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 17, 2009
Association of body mass index with decline in residual kidney function after initiation of dialysisChristiane Drechsler, Renée de Mutsert, Diana C Grootendorst, et al.Diabetes Research and Clinical Practice|May 22, 2024
Impact of empagliflozin on first and recurrent events leading to or prolonging hospitalisation in the EMPA-REG OUTCOME trialSilvio E Inzucchi, Christoph Wanner, David Fitchett, et al.Clinical Journal of the American Society of Nephrology : CJASN|November 27, 2014
Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysisChantal Kopecky, Bernd Genser, Christiane Drechsler, et al.Pageof 76